Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Immune system disorders – page 100

  • 1 664 clinical trials
  • 562 recruiting
  • 293 conditions
  • 29 countries

Conditions in this area

293 conditions with trials, the busiest first

Colitis ulcerative120Crohn's disease94Asthma89Dermatitis atopic89HIV infection78Rheumatoid arthritis75Systemic lupus erythematosus63Multiple sclerosis59Psoriasis54Psoriatic arthropathy46Myasthenia gravis44Type 1 diabetes mellitus41Systemic scleroderma40Conjunctivitis allergic34Idiopathic pulmonary fibrosis34Sjogren's syndrome31Cardiac amyloidosis29Interstitial lung disease29Immune thrombocytopenia27Endocrine ophthalmopathy26IgA nephropathy24Vitiligo24Hereditary angioedema22Axial spondyloarthritis21+269

Clinical trials in Immune system disorders

1 664 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

1 664 clinical trials

Peripheral spondyloarthritis

Not recruiting

Study on Peripheral Spondyloarthritis: Comparing Methotrexate Disodium and Golimumab for Early Remission in Adult Patients

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Golimumab
  • Sponsor:Universitair Ziekenhuis Gent

Colitis ulcerative

Not recruiting

Long-term safety study of filgotinib tablets in adults with ulcerative colitis who completed previous filgotinib treatment

Registered drug
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Filgotinib
  • Sponsor:Alfasigma S.p.A.

Dermatitis atopic

Not recruiting

Study on Tralokinumab for Children Aged 6-11 with Moderate-to-Severe Atopic Dermatitis

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:0–17 years
  • Substances:Tralokinumab
  • Sponsor:Leo Pharma A/S

Crohn's disease

Not recruiting

Study on the Effects of Etrasimod Arginine for Patients with Moderate to Severe Crohn's Disease

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Etrasimod Arginine
  • Sponsor:Arena Pharmaceuticals Inc.

Dermatomyositis

Not recruiting

Study on Baricitinib for Treating New-Onset Juvenile Dermatomyositis in Children

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years
  • Substances:Baricitinib
  • Sponsor:Assistance Publique Hopitaux De Paris

HIV infection

Not recruiting

Study Comparing DTG/3TC and BIC/FTC/TAF for Maintaining HIV Control in Adults

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Bictegravir
  • Sponsor:Fundacion Seimc Gesida

Multiple sclerosis

Not recruiting

Study on the Effectiveness of Tamsulosin for Treating Urinary Symptoms in Women with Multiple Sclerosis

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Tamsulosin Hydrochloride
  • Sponsor:Centre Hospitalier Universitaire De Nimes

Psoriasis

Not recruiting

Study of deucravacitinib in adults with plaque psoriasis: Effects on immune system cells

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Deucravacitinib
  • Sponsor:Charite Universitaetsmedizin Berlin KöR

Encephalitis autoimmune

Not recruiting

Study on the Effects of Satralizumab for Patients with Autoimmune Encephalitis (NMDAR or LGI1)

Registered drug
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years · 65+ years
  • Sponsor:F. Hoffmann-La Roche AG

Myasthenia gravis

Not recruiting

Study on the Effects of Efgartigimod Alfa for Patients with Generalized Myasthenia Gravis

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Efgartigimod Alfa
  • Sponsor:Argenx

Rheumatoid arthritis

Not recruiting

Study on Spironolactone for Treating Active Rheumatoid Arthritis in Patients

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Spironolactone
  • Sponsor:Les Hopitaux Universitaires De Strasbourg

HIV infection

Not recruiting

Study on Reducing HIV Latent Reservoirs Using High Doses of Lamivudine, Maraviroc, and Dolutegravir Sodium for Patients with HIV Infection

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years
  • Substances:Dolutegravir Sodium
  • Sponsor:Fundacion Para La Investigacion Biomedica Del Hospital Universitario Ramon Y Cajal

Substances studied in this area

The therapies tested most often in Immune system disorders trials.

Sodium Chloride61 clinical trialsRituximab50 clinical trialsPrednisone47 clinical trialsAdalimumab40 clinical trialsEmtricitabine40 clinical trialsTenofovir Alafenamide38 clinical trialsTocilizumab38 clinical trialsMethotrexate37 clinical trialsPrednisolone35 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.